Varex Imaging Corp Dossier - Source-backed chat

Varex Imaging Corp

VREXNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.92

Intrinsic Value $17.25median of 5 methods · middle span $16-$17based on filings through 3 Jul 2026

Market Price $18.45Price as of 30 Sep 2026

Near fair valueIntrinsic value is 6% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $783.5M

Enterprise Value $1B

Shares Outstanding 42.6M diluted

Moat Rating Narrow

Next Earnings Date17 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Varex Imaging Corp (VREX) occupies a critical upstream position as a leading independent supplier of X-ray tubes, digital detectors, and software components for medical and industrial OEMs. While the company's long-term outlook is supported by secular trends in advanced diagnostics (such as photon counting and AI-enabled imaging) and cargo security, near-term performance remains constrained by high inventory levels, soft cash flow generation, and geographic headwinds in regions like EMEA. The successful completion of its debt refinancing in early 2026 has stabilized the balance sheet, but execution on its newly reinstated full-year fiscal 2026 guidance is critical to restoring investor confidence.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.00

Mean target$18.00

High · most bullish analyst$22.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$14.5015%

Persistent customer destocking and prolonged economic softness in key markets like China and EMEA suppress OEM demand, causing fiscal 2026 revenue to fall below the guided range. High fixed costs and rising input expenses continue to compress gross margins. Slow inventory turnover leads to further operating cash outflows, and net debt leverage rises back above historical comfort levels.

Base CaseCentral scenario

$16.1760%

Varex achieves its reinstated fiscal year 2026 guidance, with revenue landing between $860 million and $880 million and non-GAAP EPS of $0.80 to $1.00. Medical segment revenue grows moderately at 2-3% year-over-year, supported by stable CT demand, while the industrial segment continues to expand at a low single-digit rate. Working capital pressures gradually ease as inventory is converted to shipments, stabilizing operating cash flow.

Bull CaseUpside scenario

$18.0025%

Accelerated adoption of next-generation photon counting detectors across multiple medical modalities and rapid commercialization of high-throughput sources like the XRpure XR16. Strong execution in the industrial segment, driven by global cargo security and non-destructive testing demand, expands margins beyond historical averages. Supply chain localization in India and China successfully reduces logistics costs and mitigates tariff impacts, driving non-GAAP EPS to the high end of guidance.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Upstream market leadership with a highly specialized product portfolio critical to medical and industrial imaging systems.
Strong technological pipeline, including active engagements with eight medical imaging OEMs for photon counting detectors.
Improved balance sheet flexibility following the successful completion of debt refinancing in March 2026, which reduced gross debt and lowered interest expenses.
Reinstatement of full-year guidance, signaling management's increased visibility and confidence in second-half fiscal 2026 demand trends.

Key Investment Risks

Significant customer concentration, with a substantial portion of revenue derived from a limited number of top OEM customers.
Potential direct competition from its own OEM customers who may choose to vertically integrate and develop proprietary imaging components.
Supply chain vulnerability due to reliance on a limited number of specialized component suppliers.
Working capital constraints driven by elevated inventory levels and negative operating cash flows in recent quarters.

Thesis Invalidation Triggers

Fiscal year 2026 revenue falling below the lower bound of the guided $860 million range.
Non-GAAP gross margin dropping below 33% on a sustained basis due to persistent input cost inflation or unfavorable product mix.
Loss of one or more key OEM customer relationships to vertical integration or competitors.
Failure to transition operating cash flow back to positive territory by the end of fiscal year 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.